Patrick Campbell

The January 2023 endocrinology month in review features coverage of the FDA’s approval of bexagliflozin, news surrounding semaglutide, and the introduction of an expert-led, diabetes-focused podcast to HCPLive Endocrinology.

A systematic review and meta-analysis of nearly 3 dozen published articles details the apparent increase in risk of cardiovascular disease and diabetes associated with a diagnosis of autism.

The January 2023 cardiology month in review features a trio of articles related to management of atrial fibrillation, the FDA approval of Abbott’s Navitor system, and a study spotlighting the prevalence of mental health conditions among cardiologists.

An analysis of registry data recorded in Denmark over a 4-decade period offers an overview of the risk of acute myocardial infarction and ischemic stroke incurred as a result of preeclampsia during pregnancy and how this risk changes over time.

A study of more than 100 adults with type 1 diabetes suggests those with increased levels of self-stigma had worse glucose control than their counterparts with lower levels of self-stigma.

A meta-analysis with data from more than 30 published articles provides an overview of associations between calprotectin levels and disease activity, treatment response, and inflammation among patients with rheumatoid arthritis.

A study of health care professionals' opinions of the ease of use and utility of the SmartClic/ClicWise autoinjector provides insight into the use of the device for patients with rheumatic conditions.

With up to 40 years of follow-up, a retrospective study of matched pairs is providing an overview of the long-term risks and benefits of bariatric surgery in people with overweight or obesity.

An analysis of 2 decades worth of data from the Clinical Practice Research Datalink suggests all-cause mortality rates in type 2 diabetes have decreased but sheds light on upward trends in mortality from multiple different forms of cancer, including pancreatic, liver, and lung cancer, particularly among older patients.

Announced on January 24, the US FDA's marketing clearance for the Tidepool Loop mobile app allows for use with compatible devices for automated insulin dosing to help manage type 1 diabetes in persons 6 years of age and older.

The SPRINT MIND trial is providing new evidence related to the effects of intensive blood pressure lowering on cognitive impairment and risk of dementia according to baseline diastolic blood pressure

A prospective, dual-center study of people with high-risk type 1 diabetes using multiple daily injections aged 13-25 years demonstrates the utility of this technology in this patient population.

Announced on January 23, the US FDA's approval of bexagliflozin (Brenzavvy) was awarded to TheracosBio and indicates the SGLT2 inhibitor for use as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.

A new study from clinicians in the VA Boston Healthcare System provides an overview of the impact the COVID-19 pandemic has had on racial disparities in wait times for new cardiology and orthopedic specialist consultations.

Using data from the STEP 5 trial, investigators provide new insight into the effects of semaglutide 2.4 mg on hunger and cravings among people with overweight and obesity, with results also shedding light on how these effects correlate to weight loss in the trial.

An analysis of data from the STS Adult Cardiac Surgery Database provides an updated overview of the risks of mortality, morbidity, and conversion-to-replacement among patients undergoing mitral valve repair for primary mitral regurgitation.

A phase 4, post-marketing surveillance study in Korea provides insight into the safety and efficacy of SB2, an infliximab biosimilar, across a wide range of immune-mediated inflammatory diseases, including rheumatoid arthritis, ulcerative colitis, and ankylosing spondylitis.

In what investigators are calling the largest study of its kind ever conducted in the US, results of the 2-year study, which included more than 300 transgender or nonbinary youth, underline the positive benefits seen with receipt of gender-affirming hormone therapy among this patient population.

Results of the PREVENT CLOT study indicate use of aspirin was as effective as low-molecular-weight heparin for reducing incidence of mortality in patients hospitalized with a traumatic fracture.

Using data from more than 500 patients with more than 6 years of follow-up suggests total caloric intake may be more effective for reducing weight loss than increasing the time between meals.

A posthoc analysis of the VITAL study suggests the potential benefit of vitamin D supplementation could depend on a person's body mass index, with results indicating a decreased response to therapy as BMI category increased.

Comparing MTO scanning against adrenal vein sampling, investigators in the UK found the noninvasive diagnostic option could improve the identification of primary aldosteronism and candidates for adrenalectomy.

An analysis of a commercial claims database offers insight into the increase in vision-threatening eye disease among people with diabetes aged younger than 65 years from 2009-2018, with results also detailing trends in anti-VEGF therapy during the same period.

A study examining associations between coffee metabolites and risk of NAFLD severity suggests people with type 2 diabetes had a lower risk of fibrosis and more severe NAFLD based on increased coffee consumption.

An analysis of NHANES data from 1999-2018 details the progress made with regard to cholesterol management on a population level but also provides insight into areas where room for improvement still exists.

Announced by Novo Nordisk on January 12, the label update from the FDA removes a previous indication stating oral semaglutide (Rybelsus) should not be used as an initial therapy, which clears the way for the agent to be used as a first-line therapy in type 2 diabetes.

A simulation study including both cardiologists and pulmonologists found providers failed to properly diagnose pulmonary hypertension more than 50% of the time.

Using data from the SEARCH for Diabetes in Youth study, a new analysis suggests rates of type 1 diabetes in youth may increase by 65% between now and 2060, while rates of type 2 diabetes could increase more than 600% during that same period if left unchecked.

An analysis of data from type 1 diabetes prevention trials is shedding new light on factors associated with increased and decreased likelihood of screening for type 1 diabetes among participants considered eligible for each trial.

A systematic review and meta-analysis of observational studies of people with diabetes suggest more than 1-in-4 also had a diagnosis of osteoporosis.